MINGHETTI, PAOLA
MINGHETTI, PAOLA
Dipartimento di Scienze Farmaceutiche
Relevant factors to guarantee quality of oligonucleotide-based products
2026 S. Azari, S. Manellari, G. Anderluzzi, P. Minghetti, U.M. Musazzi
Regulatory aspects of 3D printing systems in healthcare
2025 P. Minghetti, U.M. Musazzi, P. Rocco
Bergamot waste derived lipid nanosystems as novel excipients for (trans)dermal drug delivery
2025 P. Volonté, C. Ricci, S. Arnoldi, G. Roda, E. DEL FAVERO, F. Puoci, P. Minghetti, S. Franze', F. Cilurzo
Messenger RNA (mRNA) based therapeutics in transforming cardiovascular care: Progress, regulatory challenges and future perspectives
2025 M. Khan, U.M. Musazzi, S. Manellari, N. Mouawad, G. Damiano, R. Rinaldi, A. Raucci, S. Costantino, F. Paneni, P. Minghetti, G. Pompilio, M.C. Vinci
Back to gene therapy: bringing the EU regulation into the future
2025 U.M. Musazzi, P. Rocco, S. Manellari, S. Azari, G. Pompilio, P. Minghetti
Patient-managed digital medical devices: Do we need further regulation?
2024 P. Minghetti, U.M. Musazzi, S. Manellari, V. Pagella, P. Rocco
Updating ‘Data on the determination of human epidermis integrity in skin permeation experiments by electrical resistance’ with Data on pig ear skin
2024 P. Volonte', U.M. Musazzi, C. Gennari, A. Casiraghi, F. Cilurzo, P. Minghetti
β-galactosidase orodispersible dosage forms for the treatment of lactose intolerance
2024 U.M. Musazzi, C. Meazzini, G. Anderluzzi, G. Frigerio, F. Selmin, P. Minghetti, F. Cilurzo
Pediatric oral extemporaneous preparations and practices: International Pharmaceutical Federation (FIP) global study
2024 H.M. Fadda, H. Weiler, M. Carvalho, Y.Z. Lee, H. Dassouki, R. Abublan, S. Iurian, A. Hamid, G. Şeremet, Z. Li, C. Tuleu, P. Minghetti, G.M. Pauletti
Equivalence assessment of creams with quali-quantitative differences in light of the EMA and FDA regulatory framework
2024 P. Volonte', U.M. Musazzi, L. Arnaboldi, M.A. Ortenzi, A. Casiraghi, F. Cilurzo, P. Minghetti
Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
2023 S. Crisafulli, P. Maria Cutroneo, N. Luxi, A. Fontana, C. Ferrajolo, P. Marchione, L. Sottosanti, G. Zanoni, U. Moretti, S. Franze', P. Minghetti, G. Trifirò
Cases of drug repositioning in children's orphan drugs: Licenced drugs versus unlicenced magistral preparations
2023 D. Zanon, U.M. Musazzi, M. Cirino, G. Bennati, A. Casiraghi, N. Maximova, E. Barbi, P. Minghetti
Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union
2023 S. Manellari, U.M. Musazzi, P. Rocco, P. Minghetti
Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges
2023 U.M. Musazzi, S. Franze, F. Condorelli, P. Minghetti, P. Caliceti
Nature of the Interaction of Alpha-D-Mannose and Escherichia coli Bacteria, and Implications for its Regulatory Classification. A Delphi Panel European Consensus Based on Chemistry and Legal Evidence
2023 F. Scaglione, P. Minghetti, F. Ambrosio, B. Ernst, V. Ficarra, M. Gobbi, K. Naber, H. Schellekens
Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations
2023 P. Bongiorno, A. Lopalco, A. Casiraghi, P.A. Spennacchio, A. Pitruzzella, A. Assunta Lopedota, P. Minghetti, N. Denora
Drug repositioning: when compounding is worth for children treating
2022 U.M. Musazzi, D. Zanon, M. Cirino, P. Minghetti
Olanzapine orodispersible films: how preparation methods can impact on the biopharmaceutic performances
2022 U.M. Musazzi, F. Selmin, F. Cilurzo, P. Minghetti
Drug repositioning: is it always worth?
2022 U.M. Musazzi, D. Zanon, P. Minghetti
The European resilience to medicines’ shortages through the pandemic
2022 U.M. Musazzi, P. Minghetti